Ticker: ENGNW

Quick take - enGene Holdings Inc. (NASDAQ: ENGNW) Clinical‑stage biotech advancing its lead candidate detalimogene in the Phase 1/2 LEGEND program and preparing a planned BLA filing in 2H 2026. Financials show a deliberate ramp in R&D and headcount, funded by cash + marketable securities, a term ...

enGene Holdings Inc. (NASDAQ: ENGNW) is a clinical-stage biotechnology company focused on developing genetic medicines, with its primary candidate being detalimogene voraplasmid (formerly EG-70) aimed at treating bladder cancer. The company reported significant financial developments in its lates...

enGene Holdings Inc. (NASDAQ: ENGNW) - Q1 2025 Analysis enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing innovative genetic therapies, particularly for bladder cancer. Its lead candidate, detalimogene voraplasmid, is designed to induce a local immune response a...